Abstract Migraine is one of the most prevalent and disabling diseases in the world. Migraine attack treatments and prophylactic treatments of this disease are essential to lessen its individual, social, and economic impact. This is a narrative review of the main drugs used for treating migraine, as well as the experimental models and the theoretical frameworks that led to their development. Ergot derivatives, triptans, non-steroid anti-inflammatory drugs, tricyclic antidepressants, beta-blockers, flunarizine, valproic acid, topiramate, onabotulinumtoxin A, ditans, monoclonal antibodies against CGRP and its receptor, and gepants are discussed. Possible therapeutic targets for the development of new drugs that are under development are also addressed. Many of the drugs currently in use for treating migraine were developed for the treatment of other diseases, but have proven effective for the treatment of migraine, expanding knowledge about the disease. With a better understanding of the pathophysiology of migraine, new drugs have been and continue to be developed specifically for the treatment of this disease. world individual social impact derivatives triptans nonsteroid non steroid antiinflammatory anti inflammatory antidepressants betablockers, betablockers beta blockers, blockers beta-blockers flunarizine acid topiramate A ditans receptor discussed addressed

Resumo A migrânea é uma das doenças mais prevalentes e incapacitantes do mundo. O tratamento da crise de migrânea e o tratamento profilático da doença são essenciais para diminuir o seu impacto individual, social e econômico. Este é um artigo de revisão narrativa. Revisamos as principais drogas usadas para a migrânea e os modelos experimentais e referenciais teóricos que levaram ao seu desenvolvimento. Foram abordados os derivados do ergot, triptanas, anti-inflamatórios não hormonais, antidepressivos tricíclicos, betabloqueadores, flunarizina, ácido valproico, topiramato, toxina onabotulínica do tipo A, os ditans, anticorpos monoclonais contra o CGRP e seu receptor e os gepants. Também foram abordados possíveis alvos terapêuticos para o desenvolvimento de novas drogas e drogas que estão em desenvolvimento para o tratamento da migrânea. Muitas das drogas usadas atualmente foram desenvolvidas para o tratamento de outras doenças e se mostraram efetivas para o tratamento da migrânea. Essas ajudaram a ampliar o conhecimento sobre a doença. Com o melhor entendimento da fisiopatologia da migrânea, novas drogas foram e estão sendo desenvolvidas especificamente para o tratamento dessa doença. mundo individual econômico narrativa ergot triptanas antiinflamatórios anti inflamatórios hormonais tricíclicos betabloqueadores flunarizina valproico topiramato ditans gepants

Resumo Antecedentes A avaliação e o tratamento das cefaleias primárias e secundárias são um desafio global de saúde pública. Reconhecendo o impacto epidemiológico das cefaleias, um grupo de pesquisadores vinculados à Sociedade Brasileira de Cefaleia propôs a criação de um Registro Brasileiro de Cefaleia e elaborou seu protocolo inicial. Objetivo Nesta publicação descrevemos os métodos e dados preliminares obtidos a partir do estudo piloto. Métodos Trata-se de um estudo prospectivo observacional longitudinal multicêntrico, realizado entre setembro de 2020 e agosto de 2021. Foram coletados dados em três centros especializados no atendimento de cefaleia, em estados da região sul e sudeste do Brasil. Pacientes com idade igual ou superior a 18 anos que procuraram os centros terciários por queixa de cefaleia e concordaram em participar do estudo foram considerados elegíveis. Resultados Sessenta e seis pacientes foram incluídos no estudo piloto, 43 (65%) do Rio Grande do Sul e 23 (35%) de Minas Gerais. Da amostra total, 90% eram do sexo feminino e a idade média dos sujeitos foi de 38,2 ± 11,2 anos. As cefaleias primárias representaram 85,3% dos diagnósticos realizados. Entre as cefaleias secundárias, a cefaleia por uso excessivo de medicamentos foi a mais frequente (7,1%). Conclusões O estudo piloto evidenciou a viabilidade do protocolo de pesquisa desenvolvido para centros terciários. O Registro Brasileiro de Cefaleia constituirá uma fonte de dados longitudinais com o objetivo de contribuir para melhor caracterização dos diversos fenótipos de pacientes com cefaleias primárias e secundárias, detalhar o uso de recursos de saúde e identificar preditores de melhores desfechos clínicos. pública inicial Tratase Trata se multicêntrico 202 2021 Brasil 1 elegíveis 4 65% 65 (65% 2 35% 35 (35% Gerais total 90 382 38 38, 112 11 11, 853 85 3 85,3 realizados 7,1%. 71 7,1% . 7 (7,1%) clínicos 20 6 (65 (35 9 8 85, 7,1 (7,1% (6 (3 7, (7,1 ( (7, (7

Abstract Background Evaluation and treatment of primary and secondary headaches is a global public health challenge. Recognizing the epidemiological impact of headaches, a group of researchers linked to the Brazilian Headache Society proposed the Brazilian Headache Registry and drew up its initial protocol. Objective Here we describe the methods and preliminary data obtained from the pilot study. Methods This was a multicenter longitudinal observational study conducted between September 2020 and August 2021. Prospective data were collected in three specialist centers for headache care in states in southern and southeastern Brazil. Patients aged 18 years or older who sought care for headache in tertiary centers and who agreed to participate in the study, were considered eligible. Results Sixty-six patients were included in the pilot study: 43 (65%) from Rio Grande do Sul state and 23 (35%) from Minas Gerais state. Overall, 90% were female, and the subjects' mean age was 38.2 ± 11.2 years. Primary headaches accounted for 85.3% of the diagnoses made. Among secondary headaches, medication overuse headache was the most frequent type (7.1%). Conclusions The pilot study showed the feasibility of the research protocol developed for tertiary centers. The Brazilian Headache Registry will form a source of longitudinal data with the aim of contributing to better characterization of the various phenotypes of patients with primary and secondary headaches, and to detailing the use of health resources and identifying predictors of better clinical outcomes. challenge 202 2021 Brazil 1 eligible Sixtysix Sixty six 4 65% 65 (65% 2 35% 35 (35% Overall 90 female subjects 382 38 38. 112 11 11. 853 85 3 85.3 made 7.1%. 71 7.1% . 7 (7.1%) outcomes 20 6 (65 (35 9 8 85. 7.1 (7.1% (6 (3 7. (7.1 ( (7. (7

Resumo Antecedentes A cefaleia atribuída ao acidente vascular cerebral isquêmico (AVCi) tem uma frequência de 7,4% a 34% dos casos. Apesar de ser considerada frequente, esta cefaleia ainda é pouco estudada em termos de seus fatores de risco e características. Objetivo Avaliar a frequência e as características clínicas da cefaleia atribuída ao AVCi e os fatores associados com a sua ocorrência. Métodos Este foi um estudo transversal que incluiu pacientes admitidos consecutivamente com até 72 horas do início do AVCi. Foi utilizado um questionário semiestruturado. Os pacientes realizaram ressonância magnética. Resultados Foram incluídos 221 pacientes, 68,2% dos quais eram do sexo masculino, e com idade média de 68,2 ± 13,8 anos. A frequência da cefaleia atribuída ao AVCi foi de 24,9% (intervalo de confiança de 95% [IC95%]: 19,6-31,1%). A duração mediana da cefaleia foi de 21 horas, e ela se iniciou com mais frequência ao mesmo tempo em que o déficit focal (45,3%), teve instalação gradual (83%), foi de moderada intensidade, pulsátil (45,3%), bilateral (54,6%) e teve um padrão semelhante ao da cefaleia de tipo tensional (53,6%). A cefaleia atribuída ao AVCi esteve significativamente associada à cefaleia de tipo tensional prévia, e à migrânea com e sem aura prévias (regressão logística). Conclusão A cefaleia atribuída ao AVCi é frequente, tem padrão mais habitual semelhante ao da cefaleia de tipo tensional, e está associada aos antecedentes de cefaleia de tipo tensional e migrânea. (AVCi 74 7 4 7,4 34 casos frequente ocorrência semiestruturado magnética 22 682 68 2 masculino 68, 138 13 8 13, anos 249 24 9 24,9 intervalo 95 IC95% IC95 IC [IC95%] 19,631,1%. 196311 19,6 31,1% . 19 6 31 1 19,6-31,1%) 45,3%, 453 45,3% , 45 3 (45,3%) 83%, 83 83% (83%) intensidade 54,6% 546 54 (54,6% 53,6%. 536 53,6% 53 (53,6%) prévia regressão logística. logística logística) 7, 24, IC9 [IC95% 631 19,631,1% 19631 196 19, 311 31,1 19,6-31,1% 45,3 (45,3% (83% 54,6 5 (54,6 53,6 (53,6% [IC95 63 19,631,1 1963 31, 19,6-31,1 45, (45,3 (83 54, (54, 53, (53,6 [IC9 19,631, 19,6-31, (45, (8 (54 (53, [IC 19,631 19,6-31 (45 ( (5 (53 19,63 19,6-3 (4 19,6-

Abstract Background It is estimated that headache attributed to ischemic stroke occurs in 7.4% to 34% of the cases. Despite its frequency, this headache has been little studied in terms of its risk factors and characteristics. Objective To assess the frequency and clinical characteristics of headache attributed to ischemic stroke and the factors associated with its occurrence. Methods The present was a cross-sectional study which included patients consecutively admitted within 72 hours of the onset of ischemic stroke. A semi-structured questionnaire was used. The patients underwent magnetic resonance imaging. Results A total of 221 patients were included, 68.2% of whom were male, and the mean age was of 68.2 ± 13.8 years. The frequency of headache attributed to ischemic stroke was of 24.9% (95% confidence interval [95%CI]: 19.6-31.1%). The headache had a median duration of 21 hours and most frequently began at the same time as the focal deficit (45.3%), with a gradual onset (83%). It was of moderate intensity, pulsatile (45.3%), bilateral (54.6%), and presented a similar pattern to that of tension-type headache (53.6%). Headache attributed to stroke was significantly associated with previous tension-type headache, and previous migraine with and without aura (logistic regression). Conclusion Headache attributed to stroke is common, with a pattern similar to that of tension-type headache, and it is associated with a history of tension-type and migraine headaches. 74 7 4 7.4 34 cases occurrence crosssectional cross sectional semistructured semi structured used imaging 22 682 68 2 male 68. 138 13 8 13. years 249 24 9 24.9 95% 95 (95 95%CI 95CI CI [95%CI] 19.631.1%. 196311 19.6 31.1% . 19 6 31 1 19.6-31.1%) 45.3%, 453 45.3% , 45 3 (45.3%) 83%. 83 83% (83%) intensity 54.6%, 546 54.6% 54 (54.6%) tensiontype tension type 53.6%. 536 53.6% 53 (53.6%) logistic regression. regression regression) common headaches 7. 24. (9 [95%CI 631 19.631.1% 19631 196 19. 311 31.1 19.6-31.1% 45.3 (45.3% (83% 54.6 5 (54.6% 53.6 (53.6% ( 63 19.631.1 1963 31. 19.6-31.1 45. (45.3 (83 54. (54.6 53. (53.6 19.631. 19.6-31. (45. (8 (54. (53. 19.631 19.6-31 (45 (54 (53 19.63 19.6-3 (4 (5 19.6-

ABSTRACT BACKGROUND: Moonlighting is a largely discussed, however under-explored, subject among physician residents. OBJECTIVES: To analyze the frequency of moonlighting and its related factors. DESIGN AND SETTING: This cross-sectional study enrolled medical residents from all geographical regions of Brazil. METHODS: A web-based structured closed-ended survey was applied that explored the frequency and type of moonlighting, residency programs characteristics, and psychological distress. The questionnaire was published on social networks. RESULTS: The completion rate was 71.4% (n = 1,419) and 37.7% were males aged 28.8 ± 3.2 (mean ± standard deviation) years, and 571 (40.2%) were post-graduate year (PGY) 1. There were residents from 50 medical specialties (the most common training area was clinical, 51.9%). A total of 80.6% practiced moonlighting, with an average weekly workload of 14.1 ± 9.4 h, usually overnight or in weekend shifts. Factors related to it were being PGY-2 or higher (adjusted odds ratio = 3.90 [95% confidence interval = 2.93–5.18], logistic regression), lower weekly residency duty hours (0.98 [0.97–0.99]), and a higher salary (1.23 [1.08–1.40]). In contrast, perception of a “fair/adequate” compensation was influenced by age (1.02 [1.01–1.02]), not being single (1.05 [1.01–1.10]), and residency duty hours (1.51 [1.22–1.88]). Depression, anxiety, diurnal somnolence scores, and work-personal life conflicts were not correlated with moonlighting status. CONCLUSION: Moonlighting frequency is high, and it is related to higher PGY, briefer residency duty hours, and the perception that remuneration should be higher. This study provides insights into the motivations for moonlighting and effort-reward imbalance. BACKGROUND discussed underexplored, underexplored under explored, under-explored OBJECTIVES factors SETTING crosssectional cross sectional Brazil METHODS webbased web based closedended closed ended characteristics distress networks RESULTS 714 71 4 71.4 n 1,419 1419 1 419 377 37 7 37.7 288 28 8 28. 32 3 2 3. mean deviation years 57 40.2% 402 40 (40.2% postgraduate post graduate PGY (PGY 5 clinical 51.9%. 519 51.9% . 51 9 51.9%) 806 80 6 80.6 141 14 14. 94 9. h shifts PGY2 PGY- adjusted 390 90 3.9 95% 95 [95 2.93–5.18, 293518 2.93–5.18 , 93 18 2.93–5.18] regression, regression regression) 0.98 098 0 98 (0.9 0.97–0.99, 097099 0.97–0.99 97 99 [0.97–0.99]) 1.23 123 23 (1.2 1.08–1.40. 108140 1.08–1.40 08 [1.08–1.40]) contrast fair/adequate fairadequate fair adequate “fair/adequate 1.02 102 02 (1.0 1.01–1.02, 101102 1.01–1.02 01 [1.01–1.02]) 1.05 105 05 1.01–1.10, 101110 1.01–1.10 10 [1.01–1.10]) 1.51 151 (1.5 1.22–1.88. 122188 1.22–1.88 22 88 [1.22–1.88]) Depression anxiety scores workpersonal work personal status CONCLUSION high effortreward effort reward imbalance 71. 1,41 41 37. 40.2 (40.2 51.9 80. 39 [9 29351 2.93–5.1 0.9 09 (0. 09709 0.97–0.9 [0.97–0.99] 1.2 12 (1. 10814 1.08–1.4 [1.08–1.40] 1.0 10110 1.01–1.0 [1.01–1.02] 10111 1.01–1.1 [1.01–1.10] 1.5 15 12218 1.22–1.8 [1.22–1.88] 1,4 40. (40. 51. [ 2935 2.93–5. 0. (0 0970 0.97–0. [0.97–0.99 (1 1081 1.08–1. [1.08–1.40 1011 1.01–1. [1.01–1.02 [1.01–1.10 1221 1.22–1. [1.22–1.88 1, (40 293 2.93–5 ( 097 0.97–0 [0.97–0.9 108 1.08–1 [1.08–1.4 101 1.01–1 [1.01–1.0 [1.01–1.1 122 1.22–1 [1.22–1.8 (4 29 2.93– 0.97– [0.97–0. 1.08– [1.08–1. 1.01– [1.01–1. 1.22– [1.22–1. 2.93 0.97 [0.97–0 1.08 [1.08–1 1.01 [1.01–1 1.22 [1.22–1 2.9 [0.97– [1.08– [1.01– [1.22– 2. [0.97 [1.08 [1.01 [1.22 [0.9 [1.0 [1.2 [0. [1. [0 [1

Resumo Antecedentes Migrânea afeta um bilhão de pessoas em todo o mundo e mais de 30 milhões de brasileiros; além disso, é um distúrbio subdiagnosticado e subtratado. Objetivo Sabe-se sobre a necessidade de difundir o conhecimento sobre o tratamento profilático da migrânea; por isso, a Sociedade Brasileira de Cefaleias (SBCe) nomeou um comitê de autores com o objetivo de estabelecer um consenso com recomendações sobre o tratamento profilático da migrânea episódica com base em artigos da literatura mundial, assim como da experiência pessoal. Métodos As reuniões foram realizadas inteiramente online, com a participação de 12 grupos que revisaram e escreveram sobre as categorias farmacológicas dos medicamentos e, ao final, reuniram-se para a leitura e conclusão do documento. As classes de medicamentos estudadas na parte II deste Consenso foram: anti-hipertensivos, inibidores seletivos de recaptação de serotonina, inibidores de recaptação de serotonina e noradrenalina, bloqueadores dos canais de cálcio, outros medicamentos e politerapia racional. Resultados Desta lista de medicamentos, apenas o candesartan foi estabelecido como eficaz no controle da migrânea episódica. Flunarizina, venlafaxina, duloxetina e pizotifeno foram definidos como provavelmente eficazes, enquanto lisinopril, enalapril, escitalopram, fluvoxamina, quetiapina, atorvastatina, sinvastatina, ciproheptadina e melatonina foram possivelmente eficazes na profilaxia da doença. Conclusões Apesar do esforço da comunidade científica em encontrarmedicamentos realmente eficazes no tratamento da migrânea, dado o grande número de medicamentos testados para este fim, ainda dispomos de poucas opções terapêuticas. 3 brasileiros disso subtratado Sabese Sabe se isso SBCe (SBCe mundial pessoal online 1 final reuniramse reuniram documento antihipertensivos, antihipertensivos anti hipertensivos, hipertensivos anti-hipertensivos noradrenalina cálcio racional Flunarizina venlafaxina lisinopril enalapril escitalopram fluvoxamina quetiapina atorvastatina sinvastatina doença fim terapêuticas

Abstract Background Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder. Objective The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience. Methods Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy. Results From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease. Conclusions Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options. 3 Brazilians besides disorder known SBCe, SBCe (SBCe acronym experience online end document antihypertensives inhibitors blockers polytherapy Flunarizine venlafaxine duloxetine lisinopril enalapril escitalopram fluvoxamine quetiapine atorvastatin simvastatin cyproheptadine disease purpose options

Resumo A Sociedade Brasileira de Cefaleia (SBCe) nomeou um Comitê de Autores com o objetivo de estabelecer um consenso com recomendações sobre o tratamento profilático da enxaqueca episódica com base em artigos da literatura mundial e da experiência pessoal. A enxaqueca é um distúrbio subdiagnosticado e subtratado que acomete um bilhão de pessoas no mundo e mais de 30 milhões de brasileiros. É conhecido na comunidade médica de neurologistas e, sobretudo, dos especialistas em cefaleia, a necessidade de se divulgar o conhecimento sobre o tratamento profilático da enxaqueca. Com esta finalidade, aliada às necessidades de atualizações de drogas e de se aumentar o conhecimento sobre a doença em si (frequência, intensidade, duração, impacto e talvez a progressão da enxaqueca), foi elaborado este Consenso, com metodologia totalmente on-line, por 12 grupos que revisaram e escreveram sobre as categorias farmacológicas das drogas e, ao final, reuniram-se para a leitura e conclusão do documento. As classes de drogas estudadas para este Consenso foram: anticonvulsivantes, antidepressivos tricíclicos, anticorpos monoclonais do antipeptídeo relacionado ao gene da calcitonina (peptídeo relacionado ao gene da calcitonina — anti-CGRP), betabloqueadores, anti-hipertensivos, inibidores dos canais de cálcio, outros antidepressivos (inibidores seletivos de recaptação de serotonina, ISRSs, e antidepressivos de ação dual), outras drogas, e politerapia. O tratamento hormonal, bem como anti-inflamatórios e triptanas em esquema de profilaxia mínima (miniprofilaxia), será abordado em um capítulo próprio. As classes de drogas estudadas na parte I do Consenso foram: anticonvulsivantes, antidepressivos tricíclicos, anticorpos monoclonais anti-CGRP, e betabloqueadores. SBCe (SBCe pessoal 3 brasileiros sobretudo cefaleia finalidade frequência, frequência (frequência intensidade duração enxaqueca, , enxaqueca) online, online on line, line on-line 1 final reuniramse reuniram documento foram anticonvulsivantes tricíclicos peptídeo antiCGRP, antiCGRP anti CGRP anti-CGRP) betabloqueadores antihipertensivos, antihipertensivos hipertensivos, hipertensivos anti-hipertensivos cálcio serotonina ISRSs dual, dual dual) politerapia hormonal antiinflamatórios inflamatórios miniprofilaxia, miniprofilaxia (miniprofilaxia) próprio CGRP, anti-CGRP (miniprofilaxia

Abstract The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers. Sociedade Cefaleia SBCe Portuguese literature experience 3 Brazilians addition disorder neurologists specialists purpose frequency, frequency (frequency intensity duration migraine, , migraine) developed methodology process document were anticonvulsants anticalcitonin anti calcitonin generelated gene related antiCGRP CGRP (anti-CGRP antibodies betablockers, betablockers beta blockers, blockers beta-blockers antihypertensives inhibitors selective SSRIs dualaction dual action antidepressants) polytherapy antiinflammatories inflammatories miniprophylaxis (miniprophylaxis chapter betablockers. blockers.

ABSTRACT BACKGROUND: Moonlighting is a largely discussed, however under-explored, subject among physician residents. OBJECTIVES: To analyze the frequency of moonlighting and its related factors. DESIGN AND SETTING: This cross-sectional study enrolled medical residents from all geographical regions of Brazil. METHODS: A web-based structured closed-ended survey was applied that explored the frequency and type of moonlighting, residency programs characteristics, and psychological distress. The questionnaire was published on social networks. RESULTS: The completion rate was 71.4% (n = 1,419) and 37.7% were males aged 28.8 ± 3.2 (mean ± standard deviation) years, and 571 (40.2%) were post-graduate year (PGY) 1. There were residents from 50 medical specialties (the most common training area was clinical, 51.9%). A total of 80.6% practiced moonlighting, with an average weekly workload of 14.1 ± 9.4 h, usually overnight or in weekend shifts. Factors related to it were being PGY-2 or higher (adjusted odds ratio = 3.90 [95% confidence interval = 2.93–5.18], logistic regression), lower weekly residency duty hours (0.98 [0.97–0.99]), and a higher salary (1.23 [1.08–1.40]). In contrast, perception of a “fair/adequate” compensation was influenced by age (1.02 [1.01–1.02]), not being single (1.05 [1.01–1.10]), and residency duty hours (1.51 [1.22–1.88]). Depression, anxiety, diurnal somnolence scores, and work-personal life conflicts were not correlated with moonlighting status. CONCLUSION: Moonlighting frequency is high, and it is related to higher PGY, briefer residency duty hours, and the perception that remuneration should be higher. This study provides insights into the motivations for moonlighting and effort-reward imbalance.

RESUMO A migrânea (enxaqueca) crônica determina uma carga pessoal, social e econômica significativa e é caracterizada por dor de cabeça presente em quinze ou mais dias por mês por ao menos três meses, com no mínimo oito dias de cefaleia migranosa a cada mês. É frequentemente associada ao uso excessivo de medicação analgésica ou antimigranosa aguda e isso não deve ser negligenciado. Este consenso foi elaborado por um grupo de membros da Sociedade Brasileira de Cefaleia, para descrever as evidências atualmente disponíveis e fornecer recomendações relacionadas ao tratamento farmacológico e não farmacológico da migrânea crônica. Estratégias de retirada na cefaleia por uso excessivo de medicamentos também são descritas, assim como os riscos dos tratamentos durante a gravidez e a amamentação. O topiramato oral e as injeções de toxina onabotulínica A são os únicos tratamentos que receberam a recomendação classe A, enquanto que o valproato, a gabapentina e a tizanidina receberam recomendação classe B, juntamente com acupuntura, biofeedback e mindfulness. Os anticorpos monoclonais anti-CGRP ou anti-CGRPr, ainda não disponíveis no Brasil, são novos fármacos promissores, já aprovados em outros países para o tratamento profilático da migrânea, cuja eficácia na migrânea crônica ainda está por ser definitivamente comprovada.

ABSTRACT Chronic migraine poses a significant personal, social and economic burden and is characterized by headache present on 15 or more days per month for at least three months, with at least eight days of migrainous headache per month. It is frequently associated with analgesic or acute migraine medication overuse and this should not be overlooked. The present consensus was elaborated upon by a group of members of the Brazilian Headache Society in order to describe current evidence and to provide recommendations related to chronic migraine pharmacological and nonpharmacological treatment. Withdrawal strategies in medication overuse headache are also described, as well as treatment risks during pregnancy and breastfeeding. Oral topiramate and onabotulinum toxin A injections are the only treatments granted Class A recommendation, while valproate, gabapentin, and tizanidine received Class B recommendation, along with acupuncture, biofeedback, and mindfulness. The anti-CGRP or anti-CGRPr monoclonal antibodies, still unavailable in Brazil, are promising new drugs already approved elsewhere for migraine prophylactic treatment, the efficacy of which in chronic migraine is still to be definitively proven.

Abstract INTRODUCTION: The number of human immunodeficiency virus-associated neurocognitive disorders has increased, reaching more than 50% of the cases. However, there are currently no substantial data on the screening methods for this disease. This study aimed to evaluate and compare the Mini-Mental State Examination to the Montreal Cognitive Assessment in human immunodeficiency virus-infected patients. METHODS: This was an observational study comprising 82 human immunodeficiency virus-positive individuals with and without cognitive complaints. RESULTS: Positive correlation (p<0.001) between the Mini-Mental State Examination and the Montreal Cognitive Assessment test scores was observed, but the mean scores revealed that the Mini-Mental State Examination showed worse performance for trails (p<0.001), cube copying (p<0.001), and clock drawing (p<0.001) than the Montreal Cognitive Assessment. CONCLUSIONS: The Mini-Mental State Examination and the Montreal Cognitive Assessment tests should be used concomitantly for the assessment of human immunodeficiency virus-associated neurocognitive disorders, but visuoexecutive and visuospatial dysfunctions are better evaluated using the Montreal Cognitive Assessment test than the Mini-Mental State Examination.

Abstract INTRODUCTION: Studies have linked human T-cell lymphotropic virus type-1 (HTLV-1) to psychiatric disease. METHODS: Patients with HTLV-1 were compared to patients seen by family doctors using a semi-structured questionnaire and the Hospital Anxiety and Depression Scale. RESULTS: Participants with (n=58) and without (n=340) HTLV were compared. Anxiety and depression were associated with greater age, being a woman, spastic paraparesis (depression: PR=4.50, 95% CI: 3.10-6.53; anxiety: PR=2.96, 95% CI: 2.08-4.21), and asymptomatic HTLV (depression: PR=4.34, 95% CI: 3.02-6.24; anxiety: PR=2.81, 95% CI: 2.06-3.85). CONCLUSIONS: Symptomatic and asymptomatic patients with HTLV-1 experienced more anxiety and depression than uninfected patients.

RESUMOCONTEXTO E OBJETIVO: Existem poucos estudos sobre quais as principais causas de atendimento nas unidades básicas de saúde do Programa de Saúde da Família. O objetivo foi descrever quais as razões que levam os pacientes a procurar quatro Unidades Básicas de Saúde da cidade do Recife, Brasil.TIPO DE ESTUDO E LOCAL: Estudo transversal em unidades básicas de saúde na cidade do Recife.MÉTODOS: Pacientes adultos consecutivamente atendidos em quatro unidades básicas de saúde na cidade do Recife tiveram as duas principais razões para o atendimento registradas por estudantes de medicina. Os estudantes não interferiram na dinâmica da consulta. A coleta de dados ocorreu entre setembro de 2010 e março de 2011 e entre novembro de 2012 e agosto de 2013. As razões para as consultas foram agrupadas em categorias mais amplas de acordo com a Classificação Internacional da Atenção Primária (ICPC-2).RESULTADOS: 478 pacientes foram incluídos, a idade média foi de 45,9 anos (± 16 anos), 71% eram do sexo feminino. A dor foi a principal razão para procura de atendimento médico (34%), seguida por avaliação de exames, renovação de receitas ou atestados médicos (17,6%). A dor musculoesquelética foi a mais frequente (15,7%), seguida por cefaleia (10,4%) e dor abdominal (8%). As principais causas de atendimento foram gerais e não específicas, musculoesqueléticas, relacionadas ao sistema nervoso e ao aparelho digestivo (ICPC-2).CONCLUSÃO: A dor foi o motivo mais frequente para procurar atendimento médico nas unidades básicas de saúde.

ABSTRACTCONTEXT AND OBJECTIVE: Only a few studies have focused on the main reasons for consultations at primary healthcare units within the Family Health Program. The aim here was to describe the reasons that led patients to seek assistance at four primary healthcare units in the city of Recife, Brazil.DESIGN AND SETTING: Cross-sectional study at primary healthcare units in the city of Recife.METHODS: Among adult patients who were consecutively attended at four primary healthcare units in the city of Recife, their two main reasons for going there were recorded by medical students. The students did not interfere in the consultation dynamics. The data were gathered between September 2010 and March 2011 and between November 2012 and August 2013. The reasons for the consultations were grouped into broader categories in accordance with the International Classification of Primary Care (ICPC-2).RESULTS: 478 patients were included. Their mean age was 45.9 years (± 16 years) and 71% were female. Pain was the main reason for seeking medical attention (34%), followed by evaluation of tests, prescription renewal and medical certificates (17.6%). The most frequent types of pain were musculoskeletal pain (15.7%), headache (10.4%) and abdominal pain (8%). The main reasons for consultation according to ICPC-2 were in the general and nonspecific, musculoskeletal, nervous system-related and digestive tract categories.CONCLUSION:Pain was the most frequent reason for seeking medical attendance at these primary healthcare units.

Relatamos o caso clínico de duas mulheres com quadro compatível com síndrome SUNCT (cefaléia de curta duração, unilateral, neuralgiforme com hiperemia conjuntival e lacrimejamento). As duas apresentavam exames clínico e neurológico normais e RM com sinais de microangiopatia. A primeira apresentava cefaléia há três anos, que ocorria várias vezes por dia, sempre que mastigava ou bocejava. Havia feito uso várias medicações sem melhora. A dor foi controlada após o uso de 600 mg de gabapentina ao dia. A segunda paciente referia cefaléia há seis meses. A dor era diária, ocorrendo de 20-40 vezes por dia. Na ocasião da primeira avaliação no ambulatório, já fazia uso 600 mg de carbamazepina ao dia e 15 mg de clorpromazina, com melhora parcial. Após introdução de gabapentina- 1200 mg/ dia, a paciente evoluiu sem dor, porém com episódios de hiperemia conjuntival.

We report the cases of two women who presented a clinical condition compatible with the SUNCT (short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing) syndrome. Both presented normal clinical and neurological examination and MRI compatible with microangiopathy. The first one related headache attacks for three years, occurring several times a day when she masticated or yawned. She had a history of multiple failed therapies. The pain was controlled after the use of gabapetin (600 mg per day). The second one related she had daily headaches for six months that occurred from 20 to 40 times per day. At the first visit to the ambulatory, she related she was using carbamazepine (600 mg per day) and chlorpromazine (15 mg per day) having a partial response. Administration of gabapentin (1200 mg per day) led to complete resolution of the pain attacks, but the patient continue to have episodes of conjunctival injection.